PPT-Immunotherapy for advanced cervical cancer

Megan Swanson MD MPH Assistant Professor Gynecologic Oncology UCSF Limited effective treatment options for advanced cervical cancer Problem when cervical cancer is advanced andor recurrent . Hazel Lewis. Public Health Physician. Wellington. Cartwright Forum, 7 August 2015. NCSP. -. R. centralised. 1965. 1990. 2000. 1988. Cartwright Report. NCSP . established . In 14 AHB. 1996. NSU. Gisborne Inquiry (CSI). The Obstetrics & Gynecological Society of Bhopal. &. AMPOGS Research Public Welfare Society. BREAST . AND GENITAL TRACT CANCER INCIDENCE RATES PER 100,000 . FEMALES worldwide. 31.3. 17.4. 8.3. Cervical Cancer Statistics. United . States. An estimated 12,000 new cases each year. An estimated 4,000 . deaths . each year . 700,000 cases of severe . pre-cancer . International. Approximately 500,000 cases expected worldwide each year!. The Future of Cancer Care. Brad . Loncar. Biotech . commentator . and . investor for 8+ . years.. Manager of a biotech-focused family office.. Franklin Templeton Investments and U.S. Department of the Treasury.. Annual CPCRN Meeting, Chicago. Tuesday, May 24. th. . Lead: Karen Glanz, PhD, MPH. Participating Sites: . UPenn. , UNC, . UWash. , CDC, NCI. This presentation was supported by Cooperative Agreement Number U48 DP005053 from the Centers for Disease Control and Prevention. The findings and conclusions in this presentation are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. . Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. What is cervical cancer?. The cervix, lower part of the uterus. Abnormal cells. Triggered by a type virus. Anatomy of the cervix. Causes of cervical cancer. The human . papillomavirus. (HPV) . Chronic infections. Cervical Cancer Statistics. United . States. An estimated 12,000 new cases each year. An estimated 4,000 . deaths . each year . 700,000 cases of severe . pre-cancer . International. Approximately 500,000 cases expected worldwide each year!. Stephanie Breda, David Czosniak, Tara Regmi, and Shaon Parial. PHM142 Fall . 2018. Instructor: . Ms. Maya Latif. Coordinator: Dr. J. Henderson. Immunotherapy. The . immune system. is crucial in the defence and protection against pathogens we may come across day to day. Any infection or disease that compromises our immune system puts us at risk of illness or death. . Presented by:. The Foundation for Women’s . Cancer. © . Updated September 2012. About this . presentation. This presentation is intended to help women take an active role in their health care. It does not replace the judgment of a health care professional in diagnosing and treating disease.. Associate Professor Philip Beale. Chair ANZGOG Clinical Trials Group. Medical Oncologist Sydney. Concord Hospital. Chris O’Brien Lifehouse. Royal Prince Alfred Hospital. Outline. Background to immunotherapy. Associate Professor Philip Beale. Chair ANZGOG Clinical Trials Group. Medical Oncologist Sydney. Concord Hospital. Chris O’Brien Lifehouse. Royal Prince Alfred Hospital. Outline. Background to immunotherapy. What Is . I. t?. The cancer of the cervix, which is caused mainly by the Human Papilloma Virus (HPV). 70% of cervical cancers and precancerous cervical lesions are caused by Types 16, 18.. Most common type is Squamous Cell Carcinoma (SCC). New treatments and new challenges. Laura Cove-Smith. Medical Oncology Consultant. The Christie NHS Foundation Trust. Manchester University NHS Foundation Trust . Session plan. Introduction to immunotherapy.